Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats

K. C. Huang, Yih-Giun Cherng, L. J. Chen, C. T. Hsu, J. T. Cheng

研究成果: 雜誌貢獻文章

5 引文 (Scopus)

摘要

A marked decrease of klotho expression was observed in the kidney of streptozotocin-induced diabetic rats (STZ rats) showing diabetic nephropathy. It has been documented that klotho is the target gene of PPARγ. However, the effect of PPARγ agonist on klotho expression in kidney of STZ rats remains obscure. Thus, we used rosiglitazone (TZD) as PPARγ agonist to investigate the effect on renal dysfunction in STZ rats. Treatment of TZD reversed the lower levels of PPARγ, klotho, and FGFR1 expressions in kidneys of STZ rats without the correction of hyperglycemia. Also, renal functions and structural defeats were improved by TZD treatment. Taken together, oral administration of TZD may improve STZ-induced diabetic nephropathy due to restoration of the expression of klotho axis through an increase in PPARγ expression without changing blood glucose in rats.

原文英語
頁(從 - 到)240-244
頁數5
期刊Hormone and Metabolic Research
46
發行號4
DOIs
出版狀態已發佈 - 2014

指紋

rosiglitazone
Peroxisome Proliferator-Activated Receptors
Rats
Streptozocin
Kidney
Diabetic Nephropathies
Hyperglycemia
Restoration
Oral Administration
Blood Glucose
Genes

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

引用此文

Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats. / Huang, K. C.; Cherng, Yih-Giun; Chen, L. J.; Hsu, C. T.; Cheng, J. T.

於: Hormone and Metabolic Research, 卷 46, 編號 4, 2014, p. 240-244.

研究成果: 雜誌貢獻文章

Huang, K. C. ; Cherng, Yih-Giun ; Chen, L. J. ; Hsu, C. T. ; Cheng, J. T. / Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats. 於: Hormone and Metabolic Research. 2014 ; 卷 46, 編號 4. 頁 240-244.
@article{a8be30047d1541808915c2728921fa70,
title = "Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats",
abstract = "A marked decrease of klotho expression was observed in the kidney of streptozotocin-induced diabetic rats (STZ rats) showing diabetic nephropathy. It has been documented that klotho is the target gene of PPARγ. However, the effect of PPARγ agonist on klotho expression in kidney of STZ rats remains obscure. Thus, we used rosiglitazone (TZD) as PPARγ agonist to investigate the effect on renal dysfunction in STZ rats. Treatment of TZD reversed the lower levels of PPARγ, klotho, and FGFR1 expressions in kidneys of STZ rats without the correction of hyperglycemia. Also, renal functions and structural defeats were improved by TZD treatment. Taken together, oral administration of TZD may improve STZ-induced diabetic nephropathy due to restoration of the expression of klotho axis through an increase in PPARγ expression without changing blood glucose in rats.",
keywords = "diabetic nephropathy, FGFR, klotho, PPARγ, STZ rat, TZD",
author = "Huang, {K. C.} and Yih-Giun Cherng and Chen, {L. J.} and Hsu, {C. T.} and Cheng, {J. T.}",
year = "2014",
doi = "10.1055/s-0033-1357161",
language = "English",
volume = "46",
pages = "240--244",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "4",

}

TY - JOUR

T1 - Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats

AU - Huang, K. C.

AU - Cherng, Yih-Giun

AU - Chen, L. J.

AU - Hsu, C. T.

AU - Cheng, J. T.

PY - 2014

Y1 - 2014

N2 - A marked decrease of klotho expression was observed in the kidney of streptozotocin-induced diabetic rats (STZ rats) showing diabetic nephropathy. It has been documented that klotho is the target gene of PPARγ. However, the effect of PPARγ agonist on klotho expression in kidney of STZ rats remains obscure. Thus, we used rosiglitazone (TZD) as PPARγ agonist to investigate the effect on renal dysfunction in STZ rats. Treatment of TZD reversed the lower levels of PPARγ, klotho, and FGFR1 expressions in kidneys of STZ rats without the correction of hyperglycemia. Also, renal functions and structural defeats were improved by TZD treatment. Taken together, oral administration of TZD may improve STZ-induced diabetic nephropathy due to restoration of the expression of klotho axis through an increase in PPARγ expression without changing blood glucose in rats.

AB - A marked decrease of klotho expression was observed in the kidney of streptozotocin-induced diabetic rats (STZ rats) showing diabetic nephropathy. It has been documented that klotho is the target gene of PPARγ. However, the effect of PPARγ agonist on klotho expression in kidney of STZ rats remains obscure. Thus, we used rosiglitazone (TZD) as PPARγ agonist to investigate the effect on renal dysfunction in STZ rats. Treatment of TZD reversed the lower levels of PPARγ, klotho, and FGFR1 expressions in kidneys of STZ rats without the correction of hyperglycemia. Also, renal functions and structural defeats were improved by TZD treatment. Taken together, oral administration of TZD may improve STZ-induced diabetic nephropathy due to restoration of the expression of klotho axis through an increase in PPARγ expression without changing blood glucose in rats.

KW - diabetic nephropathy

KW - FGFR

KW - klotho

KW - PPARγ

KW - STZ rat

KW - TZD

UR - http://www.scopus.com/inward/record.url?scp=84899480561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899480561&partnerID=8YFLogxK

U2 - 10.1055/s-0033-1357161

DO - 10.1055/s-0033-1357161

M3 - Article

VL - 46

SP - 240

EP - 244

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 4

ER -